Boston, MA -- (SBWIRE) -- 03/12/2014 -- While seasonal flu is making more headlines in Hong Kong, we highlight that the country also has a significant burden of non-communicable diseases due to sedentary lifestyles and the ageing population. The expense of treating non-communicable diseases yields strong commercial opportunities for pharmaceutical and medical devices firms, in both the public and private sectors.

Headline Expenditure Projections

- Pharmaceuticals: HKD11.24bn (US$1.45bn) in 2013 to HKD12.21bn (US$1.57bn) in 2014; +8.6% in local currency terms and US dollar terms.
- Healthcare: HKD121.94bn (US$15.69bn) in 2013 to HKD131.46bn (US$16.92bn) in 2014; +7.8% in local currency terms and US dollar terms.

Risk/Reward Ratings

Hong Kong's Pharmaceutical Risk/Reward Rating (RRR) score for Q214 is 60.2 out of 100 in our newly improved RRR system. The country scores above average for most indicators and sub-indicators, including per capita pharmaceutical expenditure, sector value growth and pensionable population. Consequently with this high score, Hong Kong is ranked seventh, above Malaysia, out of the 19 key Asia Pacific markets.

View Full Report Details and Table of Contents

Key Trends And Developments

- In January 2013, representatives from Parkway Pantai, NWS Holdings and the University of Hong Kong announced that the construction of Gleneagles Hong Kong Hospital at Wong Chuk Hang started on January 10. The Gleneagles Hong Kong Hospital is scheduled to be operational by early 2017.
- In December 2013, Helsinn and Mundipharma signed a new exclusive licence and distribution agreement, covering China, Hong Kong and Macao, for netupitant+palonosetron fixed-dose combination (FDC; NEPA), a Helsinn product under development for the treatment of chemotherapy-induced nausea and vomiting (CINV).
- In November 2013, Canada-based medical product developer Medifocus signed a joint venture agreement with Hong Kong-based Ideal Concept Group (ICG) to expedite the entry of its products in China and other Asian countries, according to the president and CEO of Medifocus, Augustine Y. Cheung. Under the terms of the agreement, ICG and Medifocus will acquire 60% and 40% stakes in the JV respectively. The JV will help Medifocus secure commercial approval for its Prolieve thermodilatation system from the China Food and Drug Administration. The approval will allow Medifocus to sell and market Prolieve as a treatment for benign prostatic hyperplasia in China.

About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

Browse all Healthcare research reports at Fast Market Research

You may also be interested in these related reports:

- Kenya Pharmaceuticals & Healthcare Report Q2 2014
- Sweden Pharmaceuticals & Healthcare Report Q2 2014
- Croatia Pharmaceuticals & Healthcare Report Q2 2014
- Mexico Pharmaceuticals & Healthcare Report Q2 2014
- Thailand Pharmaceuticals & Healthcare Report Q2 2014
- Japan Pharmaceuticals & Healthcare Report Q2 2014
- Australia Pharmaceuticals & Healthcare Report Q2 2014
- Oman Pharmaceuticals & Healthcare Report Q2 2014
- Jordan Pharmaceuticals & Healthcare Report Q2 2014
- Algeria Pharmaceuticals & Healthcare Report Q2 2014